Gene Therapy for Urea Cycle Disorders

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): This is an application from the University of Pennsylvania and the Children's National MedicalCenter to renew funding of an existing P01 entitled "Gene Therapy of Urea Cycle Disorders." We achieved the primary objectives of the current 4 year cycle of this P01. A Clinical Candidate vector was established: AAVS expressing a codon-optimized cDNA for ornithine transcarbamylase (OTC) from the liver-specific TBG promoter. In close consultation with our Ethics Advisory Board, it was decided to initially evaluate the Clinical Candidate in a phase I clinical trial in infants with late onset but severe OTC deficiency (OTCD). We will be using mechanisms to fund the clinical trial separate from this P01 competing renewal. In the conduct of our preclinical studies, we identified several issues that should be addressed before considering clinical trials in those with severe OTCD who present with life-threatening episodes of hyperammonemia as neonates. High level gene transfer in newborn mice and monkeys is acheivable, however, it diminishes to low levels due to dilution in the setting of the developing newborn liver. We also have concerns about T cell responses to some neonatal onset subjects since they may have null alleles that fail to delete T cells reactive to the normal version of OTC. Finally, some newborns will have pre-existing immunity to AAVS due to passive transfer of maternal antibodies. Project I will address issues related to T cell responses to transgene-encoded OTC and will attempt to engineer the vector genome to allow for replication when the target cell population is proliferating. Project II will evaluate novel pharmacologic interventions that could augment the efficacy of gene therapy that is less than curative. Project III will engineer the AAVS capsid to escape some level of pre-existing neutralizing antibodies. These Projects will be supported by Core laboratories that specialize in Vector, Cell Morphology and Animal Models. The deliverable at the end of the renewal application is a second generation Clinical Candidate which, in the setting of adjuvant pharmacologic therapy, is suitable for evaluation in humans with neonatal onset OTCD.